64989-46-4Relevant articles and documents
Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists
Chu, Bizhu,Jiang, Yuyang,Li, Qinyuan,Liu, Zijian,Luo, Jingyi,Shi, Zhichao,Xin, Qilei,Ye, Lizhen,Zhan, Feng,Zhang, Xun,Zhu, Qingyun
, (2021/09/20)
Chemokine receptor 2 (CXCR2) is the receptor of glutamic acid–leucine–arginine sequence-contained chemokines CXCs (ELR+ CXCs). In recent years, CXCR2-target treatment strategy has come a long way in cancer therapy. CXCR2 antagonists could block
4-phenoxyl substituted quinoline compound containing 2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one and imidazole and application of compound
-
Paragraph 0183; 0210; 0211, (2018/01/09)
The invention relates to a quinoline derivative shown as the general formula I and containing 2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one and imidazole, and pharmaceutically acceptable salt, hydrate, solvate or prodrug of the quinoline derivative. In the general formula I, Ar, R1, R2, L, and n have meanings as the description defined. The invention further relates to a great c-Met kinase inhibiting effect of the compound shown as the general formula I, and applications of pharmaceutically acceptable salt, hydrate, solvate or prodrug of the compound to prepare medicines for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, particularly an application of preparing a medicine for treating and/or preventing cancer.